Management Team

Steven W. King

President and CEO

Steve King was appointed President and CEO of Peregrine Pharmaceuticals in March 2003 and has led the company into three Phase II clinical programs.  Mr. King joined the company in 1997 as Director of R&D.  In 2000, Steve was responsible for bringing the company’s biomanufacturing facility into full cGMP compliance and then launching Peregrine’s subsidiary Avid Bioservices. Prior to joining Peregrine, Steve worked with a company that was developing Vascular Targeting Agents and with UT Southwestern Medical Center with the inventor of Peregrine’s technology.  Steve holds BS and MS degrees in Biology from Texas Tech University.


Paul J. Lytle

Chief Financial Officer

Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.


Joseph S. Shan, M.P.H.

Vice President, Clinical & Regulatory Affairs

Joseph S. Shan has served as Vice President, Clinical & Regulatory Affairs since March 2009 and previously served as our head of Clinical and Regulatory Affairs since January 2003. He is responsible for the design and execution of our clinical trials and overseeing regulatory submissions. Since joining Peregrine in 2000, Mr. Shan has been instrumental in advancing the clinical development of the Company's bavituximab and Cotara ® antibody products. Prior to joining Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory Affairs Professionals Society.


Shelley P. M. Fussey, Ph.D.

Vice President, Intellectual Property

Shelley P.M. Fussey, Ph.D. has served as our Vice President, Intellectual Property since February 2005. Dr. Fussey plays a key role in our U.S. and international patenting, patent analysis and patent defense. Dr. Fussey's expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining Peregrine, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, U.K.


Mark R. Ziebell, Esq.

Vice President, General Counsel and Corporate Secretary

Mark Ziebell was appointed Vice President and General Counsel of Peregrine Pharmaceuticals in June 2012.  Prior to joining Peregrine, Mark was a Partner at Snell & Wilmer LLP, a law firm based in Orange County, California where his practice specialized in securities law, mergers and acquisitions, corporate governance and general corporate law representing companies in a broad range of industries including the biopharmaceutical and technology sectors. In that role, Mark represented Peregrine since 1999 serving as an advisor to both management and the board of directors. Prior to Snell & Wilmer he was a Partner at the law firm of Falk, Shaff & Ziebell where he was part of the Corporate and Securities practice area. Prior to that Mark has held positions of increasing responsibility within the accounting and legal sectors. Mark holds a JD degree from the University of San Francisco, School of Law and a BA in Accounting from the University of San Francisco.


Connie Chang

Vice President, Quality

Connie Chang was appointed Vice President of Quality in October 2015.  Ms. Chang joined Peregrine in 2002 and has held a number of positions within the company. She was instrumental in leading the Process Science group that developed a number of processes which were successfully transferred into cGMP manufacturing and assays to characterize monoclonal antibodies and other proteins.  In addition, she led the CMC team efforts for multiple internal Peregrine projects, including the preparation of the CMC section for IND and other regulatory filings. In her new role, Ms. Chang is responsible for leading both Peregrine’s and its wholly-owned subsidiary Avid Bioservices’ Quality groups to ensure that the companies’ multiple manufacturing facilities operate in full compliance with US and Global quality requirements. Prior to joining Peregrine, Ms. Chang worked for a company where she was responsible for the development and validation of saliva based assays for drugs which resulted in the issuance of two patents.  Ms. Chang received her Bachelor of Science degree in Biochemistry from the California State University at Fullerton.